EUVIMEDEUVIMED entdecken
VergleichsstudieOpen Access

Comparative effectiveness of anti-seizure medications in emulated trials using medical informatics

Kevin Xie iD, Jacob Korzun, Daniel J Zhou, Ellie Chang, Nina J Ghosn, Sarah Lavelle, Arman Oganisian iD, Emily K Acton, Michael A Gelfand iD, Dan Roth, Brian Litt, Colin A Ellis

Brain · 2025

DOI: 10.1093/brain/awaf238 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Brain, 2025. Verfasst von Kevin Xie und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Bioengineering, University of Pennsylvania, Philadelphia, PA 19104, USA. Hauptthemen laut MEDLINE: Anticonvulsants, Seizures, Medical Informatics, Epilepsy. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: PCORI HHS, NINDS NIH HHS, National Institute of Neurological Disorders and Stroke of the National Institutes of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Anti-seizure medications (ASMs) are often prescribed using a trial-and-error approach with a similar sequence for many patients. Comparative effectiveness data beyond the first ASM prescription are limited. Artificial intelligence can automatically extract information from electronic health records (EHRs) and augment clinical trials. We conducted a retrospective cohort comparative effectiveness study of currently available ASMs using emulated clinical trials through a causal inference- and informatics-based framework. We extracted data from EHRs using natural language processing algorithms to collect epilepsy covariates and seizure outcomes. We compared ASMs using weighted Kaplan–Meier analyses and log-rank tests with Bonferroni corrections. We compared ASMs across seizure freedom over 2 years of follow-up, and drug retention rate over 5 years of follow-up. Emulated trials included 1596 patients (8379 patient-years) for seizure freedom as outcome and 2945 patients (14 238 patient-years) for retention as outcome. For all epilepsy types, among first-line ASMs, levetiracetam and lamotrigine were superior to oxcarbazepine for seizure freedom (P < 0.001), and levetiracetam was superior to lamotrigine and oxcarbazepine for retention (P < 0.001); among second-line ASMs, lacosamide had the best retention (P < 0.001) but lower seizure freedom rate than topiramate (P = 0.032); among third-line ASMs, cenobamate had longer retention than brivaracetam, but lower seizure freedom rate than clobazam and brivaracetam (P < 0.001). For focal epilepsies, first-line ASMs achieved similar rates of seizure freedom, but levetiracetam remained superior to lamotrigine and oxcarbazepine for retention (P < 0.001); among second-line ASMs, topiramate and lacosamide were both superior to zonisamide for seizure freedom (P < 0.001), while lacosamide remained superior to topiramate and zonisamide for retention (P < 0.002); among third-line ASMs, cenobamate, brivaracetam and clobazam achieved similar retention and seizure freedom. For generalized and unclassified epilepsies, first-line ASMs achieved similar seizure freedom, but levetiracetam remained superior to lamotrigine and oxcarbazepine for retention (P < 0.02); topiramate had the best seizure freedom among second-line ASMs (P < 0.001), while lacosamide again had better retention than zonisamide (P < 0.006); there were insufficient patients included in third-line ASM trials for this subgroup. In conclusion, emulated clinical trials provide a useful framework for studying the comparative effectiveness of anti-seizure medications using real-world observational data. Our findings of differences in seizure freedom and retention between ASMs help to generate hypotheses that should be tested in future prospective, randomized comparative effectiveness trials.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AnticonvulsantsSeizuresMedical InformaticsEpilepsyHumansRetrospective StudiesMaleFemaleElectronic Health RecordsAdultMiddle AgedTreatment OutcomeLamotrigineClinical Trials as TopicLevetiracetam

Stichwörter der Autor:innen

anti-seizure medicationscausal inferencecomparative effectivenessepilepsynatural language processing

Substanzen

AnticonvulsantsLamotrigineLevetiracetam

Autor:innen und Institutionen

  • Department of Bioengineering, University of Pennsylvania, Philadelphia, PA 19104, USA.
  • Center for Neuroengineering and Therapeutics, University of Pennsylvania, Philadelphia, PA 19104, USA.
  • Department of Neurology, University of Pennsylvania, Philadelphia, PA 19104, USA.
  • Department of Biostatistics, Brown University, Providence, RI 02903, USA.
  • Department of Biostatistics and Epidemiology, University of Pennsylvania, Philadelphia, PA 19104, USA.
  • Department of Computer and Information Science, University of Pennsylvania, Philadelphia, PA 19104, USA.

ORCID-Profile: Kevin Xie, Arman Oganisian, Michael A Gelfand

Förderung

  • PCORI HHS
  • NINDS NIH HHS
  • National Institute of Neurological Disorders and Stroke of the National Institutes of Health
  • Office of Naval Research
  • PCORI

Zitieren

APA

Xie, K., Korzun, J., Zhou, D. J., Chang, E., Ghosn, N. J., Lavelle, S., Oganisian, A., Acton, E. K., Gelfand, M. A., Roth, D., Litt, B., & Ellis, C. A. (2025). Comparative effectiveness of anti-seizure medications in emulated trials using medical informatics. Brain. https://doi.org/10.1093/brain/awaf238

Vancouver

Xie K, Korzun J, Zhou DJ, Chang E, Ghosn NJ, Lavelle S, et al. Comparative effectiveness of anti-seizure medications in emulated trials using medical informatics. Brain. 2025. doi:10.1093/brain/awaf238

BibTeX
@article{Xie2025,
  author = {Xie, Kevin and Korzun, Jacob and Zhou, Daniel J and Chang, Ellie and Ghosn, Nina J and Lavelle, Sarah and Oganisian, Arman and Acton, Emily K and Gelfand, Michael A and Roth, Dan and Litt, Brian and Ellis, Colin A},
  title = {Comparative effectiveness of anti-seizure medications in emulated trials using medical informatics},
  journal = {Brain},
  year = {2025},
  doi = {10.1093/brain/awaf238}
}
Kostenlos starten →